Hôtel-Dieu de Québec
11 Côte du Palais
CRCEO 2628
Québec, QC
Canada G1R 2J6
Dernières nouvelles
Information non disponible
Assessing Skin Cancer Risk Factors, Sun Safety Behaviors and Melanoma Concern in Atlantic Canada: A Comprehensive Survey Study
Article de revueCancers (Basel), 15 (15), 2023.
A case of eruptive xanthomas associated with pregnancy unmasking a G188E heterozygous mutation of the lipoprotein lipase gene: A case report
Article de revueSAGE Open Med Case Rep, 10 , 2022.
Analysis of Geographic and Environmental Factors and Their Association with Cutaneous Melanoma Incidence in Canada
Article de revueDermatology, 238 (6), 2022.
Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in Canada
Article de revueFront Med (Lausanne), 9 , 2022.
Reflex Molecular Testing in Melanoma Diagnosis: When Should BRAF Mutation Testing Be Ordered and Who Should Order It?
Article de revueJ Cutan Med Surg, 26 (2), 2022.
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
Article de revueCurr Oncol, 28 (5), 2021.
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Article de revueJ Immunother Cancer, 9 (10), 2021.
Asymptomatic Left Ventricular Malignant Psammomatous Melanotic Schwannoma
Article de revueCJC Open, 3 (7), 2021.
Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients
Article de revueCancers (Basel), 13 (9), 2021.
Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma
Article de revueCurr Oncol, 27 (4), 2020.
Projets actifs
- A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma, du 2023-09-14 au 2028-12-25
- Biobanque consortium oncologie, du 2023-04-01 au 2026-04-01
- Révision de cas de patients opérés par la technique de chirurgie dermatologique de type Slow Mohs pour un mélanome de type lentigo malin, du 2023-04-01 au 2025-04-01